Ann: Third Quarter Results Presentation, page-5

  1. 516 Posts.
    lightbulb Created with Sketch. 14841
    Greed is good. In my opinion we are dealing with a pretty binary outcome here. If MSB is able to replicate its previous Phase 2 results (reinforced by similar findings for the ischemic sub group data in the LVAD trial) for the 85% of ischemic patients enrolled in the phase 3 current trials, we should hope for a successful outcome. In my humble opinion, based on the bio markers of the enrolled patients group , this trial is likely to succeed because the number of MACE would have already reached its target of 540, IF, one of the cohort groups HAD NOT achieved a major reduction in hospitalisations and Terminal Cardiac Events. I explained this in greater detail on the 17th May, in my post 38618502.
    You have been warned that when the 540 MACE have been reached , Mesoblast will have definitive proof, (one way or another) that Revascor could be a blockbuster !
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.59
Change
-0.025(1.55%)
Mkt cap ! $2.031B
Open High Low Value Volume
$1.61 $1.62 $1.57 $6.345M 3.987M

Buyers (Bids)

No. Vol. Price($)
6 44493 $1.59
 

Sellers (Offers)

Price($) Vol. No.
$1.59 4159 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.